Edition:
United Kingdom

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

3.90USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$3.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,011
52-wk High
$8.60
52-wk Low
$3.78

Select another date:

Tue, May 22 2018

BRIEF-Ardelyx Announces Pricing Of Public Offering Of Common Stock

* ARDELYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ardelyx Announces Proposed Public Offering Of Common Stock

* ARDELYX INC - STARTED UNDERWRITTEN PUBLIC OFFERING OF UP TO $50 MLN OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Ardelyx Reports Qtrly Loss Per Share $0.36

* ARDELYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21

* ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Select another date: